Roche Announces Changes to Board of Directors - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Roche Announces Changes to Board of Directors

Roche has proposed that the following members of its board of directors be re-elected at the company’s annual general meeting, scheduled for March 4, 2014.

André Hoffmann, member since 1996; Dr. Andreas Oeri, member since 1996; Prof. Dr. Pius Baschera, member since 2007; Prof. Sir John Irving Bell, member since 2001; Paul Bulcke, member since 2011; Dr. Christoph Franz, member since 2011; Dame DeAnne Julius, member since 2002; Dr. Arthur D. Levinson, member since  2010; Dr. Severin Schwan, member since 2013; Peter R. Voser, member since 2011; Prof. Dr. Beatrice Weder di Mauro, member since 2006.

As announced on Sept. 16, 2013, the board proposes Christoph Franz to be elected as chairman of the board.

William M. Burns, member of the board of directors since 2010, has announced that he will not stand for re-election to the board of directors.

Source: Roche


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here